hiv/aids Programme meeting report March 2012, Siem Reap, Cambodia Executive Summary
|
|
- Vincent Golden
- 5 years ago
- Views:
Transcription
1 hiv/aids Programme meeting report WHO NIH Informal Consultation on Antiretroviral Treatment as HIV Prevention: Implementation Science in Asia March 2012, Siem Reap, Cambodia Executive Summary
2 WHO NIH Informal Consultation on Antiretroviral Treatment as HIV Prevention: Implementation Science in Asia WHO/HIV/ World Health Organization 2012 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www. who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: ; fax: ; Requests for permission to reproduce or translate WHO publications whether for sale or for noncommercial distribution should be addressed to WHO Press through the WHO web site ( The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. National Institutes of Health, Department of Health and Human Services Funding for this conference was made possible in part by National Institutes of Health (NIH). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services, nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
3 meeting report WHO NIH Informal Consultation on Antiretroviral Treatment as HIV Prevention: Implementation Science in Asia March 2012, Siem Reap, Cambodia Executive Summary
4 Meeting report June 2012 Contents 1. Background Objectives of the consultation Summary of presentations and discussions Conclusion...5 References...6 iv
5 WHO NIH Informal Consultation on Antiretroviral Treatment as HIV Prevention: Implementation Science in Asia 1. Background During , five trials that examined antiretroviral (ARV) agents for HIV prevention found a positive effect. 1,2,3,4,5 Of particular note, a clinical trial conducted by the HIV Prevention Trials Network (HPTN) showed that antiretroviral therapy (ART) reduced the risk of heterosexual transmission by 96%. 5 This trial confirmed similar results from observational studies and mathematical modelling. 6,7,8 The results had a galvanizing effect on ministries of health as well as the US President s Emergency Plan for AIDS Relief (PEPFAR) 9 and the World Health Organization (WHO). 10 Selected countries in Asia have subscribed to international commitments to reaching zero new infections 11,12 and see an opportunity to close the HIV tap by accelerating HIV prevention efforts and including earlier provision of ART as part of a comprehensive prevention plan. Three important questions have been raised in the effort to scale up ART as prevention: What is the external validity of the results from the HPTN 052 trial? Specifically, will the same prevention benefits be seen within real-world settings and beyond heterosexual couples? How can ART as prevention be translated into effective programmes implemented at scale and at what additional cost? If ART is used for prevention as well as treatment, what implementation strategy will have the greatest overall impact on the epidemic? Addressing these questions in the context of low-prevalence* and concentrated epidemics,,13 such as those found in many Asian countries, is particularly important, given the lack of studies and trials conducted in these settings. Many national AIDS programmes have the capacity for longitudinal data collection and data analysis. Furthermore, the introduction of new interventions has traditionally been preceded by feasibility studies and demonstration or pilot projects as a form of implementation research. 14 A similar approach could critically inform policy decisions and optimize the delivery and expansion of treatment as prevention in a number of Asian countries. 15,16,17 WHO is committed to a four-pronged approach: 1. Continue promoting the expansion of treatment according to the 2010 WHO recommendations Support early implementation of the 2012 WHO guidelines on couples HIV testing and counselling and ART as prevention in serodiscordant couples Promote the role of implementation science in treatment as prevention in populations among whom there are less conclusive data such as men who have sex with men, people who inject drugs and sex workers; and 4. Work towards developing a global consolidated guideline on the use of ARVs linking clinical, programmatic and operational dimensions. 20 This includes the development of metrics for monitoring and evaluating the impact of ART as prevention. *. HIV may have been present for many years but has never spread to a substantial level in any subpopulation, i.e. prevalence has not been consistently >5% in any defined subpopulation.. The spread of HIV has occurred in a defined subpopulation, i.e. prevalence is consistently >5 % in a defined subpopulation but is <1% in pregnant women. 1
6 Meeting report June 2012 Five countries in Asia Cambodia, China, Indonesia, Thailand and Viet Nam have announced plans to implement treatment as prevention in different settings and populations. These programmes and other related research projects could potentially inform the way forward for the global response to HIV/AIDS, especially within low and concentrated epidemics. In collaboration with PEPFAR and the US National Institutes of Health (NIH), WHO will promote implementation research on ART as prevention in these five countries, including the development of implementation research questions. 21,22 It is anticipated that the early programmatic and operational experience with ART as prevention in these countries will also benefit other countries by strengthening the evidence base, guiding policy decisions and helping to develop future normative guidance on the strategic use of ART for prevention and treatment. 2. Objectives of the consultation This informal consultation held from 26 to 28 March 2012 in Siem Reap, Cambodia brought together representatives of national AIDS programmes, civil society and research teams from these five countries, as well as international experts and researchers on ART as prevention. The objectives of the consultation were To discuss research issues and needs applicable to the five countries in the context of ART as prevention; To review country proposals and regional concept notes on implementation research on ART as prevention; and To identify next steps in implementing demonstration projects/research. The outcomes of the consultation will inform national programmes and WHO s guidelines. 3. Summary of presentations and discussions Commonalities between the five countries in terms of ART as prevention Existing epidemiological and HIV response data from the five national programmes suggest important commonalities, specifically: an HIV case load predominantly among key populations at higher risk (such as men who have sex with men, sex workers and people who inject drugs) and their regular sexual and/or injecting partners; low rates of HIV case-finding; and difficulty in maintaining adherence, especially among hard-to-reach, marginalized and stigmatized communities. The working definition of ART as prevention applied by participating countries was the use of ART in HIV-infected individuals irrespective of clinical staging and CD4 count. It is estimated that current treatment scale up has already averted new HIV infections. For example, in China, approximately new HIV infections have been averted. The question was also raised as to whether the continuing decrease in incident HIV cases in Cambodia and Thailand was due to high coverage following current treatment scale up. The reality of reduced investments by development partners and the increasing dependence on national budgets to fund HIV/AIDS programmes will mean optimizing both the treatment and prevention benefits of ART in the context of resource constraints. 2
7 WHO NIH Informal Consultation on Antiretroviral Treatment as HIV Prevention: Implementation Science in Asia All of these countries are emerging economies, have relatively strong national health systems and share the expressed political will to pursue introduction of highly efficacious treatment as prevention. Recent modelling efforts presented at the meeting using data from Viet Nam suggested the potential cost-effectiveness of prioritizing specific key populations at higher risk, which contribute the most to new infections, and optimizing HIV testing frequency among these groups. Similar analyses could be conducted in other countries to guide national programmes that plan to introduce ART as prevention. The feasibility and acceptability of ART as prevention approaches in these countries Many of the participating countries have taken important preparatory steps towards introducing ART as prevention. For example, China has already implemented a national policy to offer treatment irrespective of CD4 count for people living with HIV (PLHIV) who have a serodiscordant regular sexual partner. Thailand has done important work on the development of tools and processes for couples counselling, which could potentially support early ART initiation in this group. A major focus of implementation research includes identifying approaches to improve the uptake of HIV testing and retesting, acceptability of immediate treatment, retention in care and adherence to treatment. However, costs and resource allocation remain an important issue. Countries gave examples of how national programmes have attempted to assess the cost implications, cost benefit and costeffectiveness of decisions on implementing ART as prevention at scale. These include calculating the potential cost savings from initiating treatment earlier, estimating the cost of expanded HIV case-finding in low and concentrated epidemic settings, use of better tolerated but more expensive tenofovir-containing first-line ART regimens, and comparing the cost of interventions to improve treatment adherence and retention with the potential costs of increased HIV drug resistance. Box 1: Overarching questions for implementation research in Asia 1. What is the magnitude of the prevention benefit of ART in key populations such as men who have sex with men, sex workers and people who inject drugs in Asian settings? 2. How can the results of clinical trials be translated into effective programmes implemented at scale and at what additional cost? 3. In which settings should early ART be offered to have the greatest overall impact on the epidemic curve? 4. What is the appropriate mix of prevention interventions to optimize this impact? Proposed implementation science research by the five countries (Box 1) At the consultation, country teams presented concept notes for implementation science research and ongoing studies for optimizing the scale up of treatment as prevention in their 3
8 Meeting report June 2012 contexts. Each team s proposals were peer reviewed and suggestions were made for refining their research questions and methods. Ideas were exchanged on the tools and approaches developed by countries to address the cascade of interventions (i.e. HIV testing, linkages to care and treatment, retention in treatment and adherence support) necessary to make ART as prevention effective. Indonesia and Thailand presented proposals on test and treat strategies for MSM populations through clinics that offer one-stop services for multiple interventions. The Thailand study includes four sites in three geographically diverse provinces and is designed to assess the feasibility of intensified HIV testing approaches and immediate ART for prevention, including how to encourage routine testing behaviours among MSM with negative test results. In Indonesia, the study will evaluate whether intensive adherence counselling improves retention in and adherence to treatment among MSM who initiate ART before developing AIDS-related symptoms. A secondary outcome will measure the effect of STI coinfection on anal/rectal viral shedding among MSM with high levels of adherence to ART. In Cambodia and Viet Nam, the proposed feasibility studies focus on offering partner testing to persons diagnosed with HIV in existing testing and counselling services; identification of serodiscordant couples, sexual networks and risky sexual behaviours; and offering ART to index patients irrespective of CD4 count or with CD4 counts of 500 cells/mm 3. In Viet Nam, given that the majority of index patients are expected to be people who inject drugs, it will be crucial to integrate ART services with harm reduction interventions. In Cambodia, the majority of index patients are anticipated to be current and former female sex workers, allowing for further investigation of the approaches necessary to optimize ART as prevention in addition to 100% condom use promotion. China shared the extensive work done in implementing a national policy to provide ART for PLHIV with serodiscordant regular sexual partners. Through analyses of data from its routine monitoring system, China has launched efforts to identify and address some of the challenges encountered in preparing for the rapid roll-out of the policy. In keeping with this focus, China s proposed implementation science project will examine factors associated with seroconversion, including treatment side-effects and other factors associated with poor adherence among index patients on ART. Methodological issues discussed included making the best use of monitoring data to identify ways to increase the uptake of HIV testing and counselling, initiate ART earlier, increase retention and improve adherence to treatment. Adopting feasible metrics for monitoring and evaluation (M&E) of the impact of ART as prevention As ART programmes expand and include approaches to using ART as prevention, national M&E systems should adopt a set of indicators that provide critical information for programme planning and management. These could generate data to monitor and evaluate the impact of ART for both treatment and prevention, and ensure efficient use of resources. Adding a few indicators to the current routine ART monitoring used for HIV testing and ART programmes could serve to monitor the benefit of earlier ART as prevention. Participants voiced the importance of. In this context, test and treat strategies refer to programmes in which individuals diagnosed with HIV through counselling and testing services are considered eligible for ART regardless of CD4 count or clinical stage. 4
9 WHO NIH Informal Consultation on Antiretroviral Treatment as HIV Prevention: Implementation Science in Asia harmonizing both (i) the types of indicators used in universal access reporting 23 as well as (ii) the systems developed for continuous quality improvement 24 and early warning indicators for HIV drug resistance. 25 Participants also recommended investment in conducting pharmacovigilance of ARVs, 26,27 and assessment of both positive and negative changes in risk behaviours among people on ART. It is time to review the diverse existing monitoring indicators and systems and explore how they could be integrated. Due to current limitations in the availability of viral load measurement and HIV incidence assays, participants requested the development of modelling tools to support impact evaluation of ART as prevention. The development of mathematical models to help plan for and evaluate implementation research by estimating the impact of ART as prevention in a concentrated epidemic setting is an important area in which to invest resources. Participants identified costing data as critical to the evaluation of programme effectiveness for guiding resource allocation. This would require development of optimal approaches to measure unit costs for different service delivery models of both HIV testing and administering ART. Ancillary studies such as phylogenetic analysis of HIV to understand transmission patterns based on sexual networks were of great interest to investigators from China and Thailand. 4. Conclusion WHO will continue to promote translation of research to policies and programmes through its global norms and standards, and support M&E of the impact of ART as prevention. WHO seeks to foster global partnerships and extend them to regional and country activities. A key role for WHO, PEPFAR and NIH is to promote the role of implementation sciences, which includes not only the collection and analysis of data for research purposes, but also the use of routine monitoring data to strengthen programme implementation (public health evaluation), and more formal evaluation of the impact of national ART programmes. 22 Country participants requested support in a number of areas to improve the current proposals for implementation research and help ensure that the introduction of ART as prevention is effective. Facilitate sharing of experiences across countries implementing similar strategies for ART as prevention, including the dissemination of tools and materials developed to support new approaches to couples counselling, counselling for early ART initiation, adherence support, risk reduction counselling for patients on ART, and data collection/reporting formats. Facilitate the development of sustainable funding approaches for ART programmes, including those that are aimed at ART as prevention, appropriate for the resources and epidemic context in Asia. Facilitate ongoing technical support and peer review to sharpen research questions, formulate hypotheses and outline methods for implementation research proposals. 5
10 Meeting report June 2012 references 1. Abdool Karim SS et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. New England Journal of Medicine, 2010, 362: Grant RM et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine, 2010, 363: Baetan J et al., and the Partners PrEP Study Team. ARV PrEP for HIV-1 prevention among heterosexual men and women. Nineteenth Conference on Retroviruses and Opportunistic Infections, 5 8 March 2012, Seattle, Washington State, United States [Abstract number 29]. 4. Thigpen M et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. Sixth IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, July 2011 [Abstract number WELBC01]. 5. Cohen MS et al.; the HPTN 052 Protocol Team. Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine, 2011, 365(6): Anglemyer A et al. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database of Systematic Reviews, 2011, (8):CD Granich RM et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet, 2009, 373: Granich R et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness PloS One, 2012,7:e doi: / journal.pone PEPFAR Scientific Advisory Board Recommendations for the Office of the US Global AIDS Coordinator: implications of HPTN 052 for PEPFAR s Treatment Programs Available at: (accessed on 25 April 2012). 10. WHO. The strategic use of antiretrovirals for treatment and prevention of HIV: executive summary. Geneva, Switzerland, November Available at: pub/meetingreports/consultation_ pdf (accessed on 25 April 2012). 11. UNAIDS. Getting to zero: strategy. Geneva, Switzerland, UNAIDS, Available at: (accessed on 25 April 2012). 12. WHO. Global health sector strategy on HIV/AIDS Geneva, Switzerland, World Health Organization, Available at: html (accessed on 25 April 2012). 13. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance. Guidelines for second generation HIV surveillance. Geneva, Switzerland, WHO/UNAIDS, Available at: (accessed on 25 April 2012). 14. Herbst JH et al. Operational research to improve HIV prevention in the United States. Journal of Acquired Immune Deficiency Syndromes, 2012, 59: Zhou J et al. Loss to followup in HIV-infected patients from Asia-Pacific Region: results from TAHOD. AIDS Research and Treatment, 2012, Article ID ; doi: /2012/
11 WHO NIH Informal Consultation on Antiretroviral Treatment as HIV Prevention: Implementation Science in Asia 16. Srikantiah P et al. Scale-up of national antiretroviral therapy programs: progress and challenges in the Asia Pacific region. AIDS, 2010, 24 (Suppl 3):S62 S Zhang Y et al. Association between missed early visits and mortality among patients of China National Free Antiretroviral Treatment Cohort. Journal of Acquired Immune Deficiency Syndromes, 2012, 60(1): WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach revision. Geneva, Switzerland, World Health Organization, Available at: (accessed on 25 April 2012). 19. WHO. Guidance on couples HIV testing and counselling, including antiretroviral therapy for treatment and prevention in serodiscordant couples: recommendations for a public health approach. Geneva, Switzerland, WHO, Available at: guidelines/ /en/index.html (accessed on 24 April 2012). 20. WHO. The strategic use of antiretrovirals for treatment and prevention of HIV. Geneva, Switzerland, WHO. Available at consultation_ /en/index.html (accessed on 1 May 2012). 21. WHO. Alliance for Health Policy and Systems Research. Implementation research platform. Geneva, Switzerland, WHO. Available at: implementationresearch/en/ (accessed on 25 April 2012). 22. Padian NS et al. Implementation science for the US President s Emergency Plan for AIDS Relief (PEPFAR). Journal of Acquired Immune Deficiency Syndromes, 2011, 56: WHO/UNICEF/UNAIDS. A guide on indicators for monitoring and reporting on the health sector response to HIV/AIDS. February Available at: UA2012_indicator_guide_en.pdf (accessed on 25 April 2012). 24. Leatherman S et al. The role of quality improvement in strengthening health systems in developing countries. International Journal for Quality in Health Care, 2010, 22(4): Bennett DE et al. The World Health Organization s global strategy for prevention and assessment of HIV drug resistance. Antiviral Therapy, 2008, 13 (Suppl 2): Bakare et al. Global pharmacovigilance for antiretroviral drugs: overcoming contrasting priorities. PLoS Medicine, (7):e doi: /journal.pmed WHO. A practical handbook on the pharmacovigilance of antiretroviral medicines. Geneva, Switzerland, WHO, Available at: handbook/en/index.html (accessed 24 April 2012). 7
12 For more information, contact: World Health Organization Department of HIV/AIDS 20, avenue Appia, 1211 Geneva 27 Switzerland
HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS
POLICY BRIEF HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS CONSOLIDATED GUIDELINES JULY 2014 Policy brief: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for
More informationHIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS
POLICY BRIEF HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS CONSOLIDATED GUIDELINES 2016 UPDATE Policy brief: Consolidated guidelines on HIV prevention, diagnosis, treatment and care
More informationMultidrug-/ rifampicinresistant. (MDR/RR-TB): Update 2017
Multidrug-/ rifampicinresistant TB (MDR/RR-TB): Update 2017 The global TB situation (1) Estimated incidence, 2016 Estimated number of deaths, 2016 All forms of TB HIV-associated TB Multidrug- / rifampicin-resistant
More informationAntiretroviral therapy for adults and adolescents KEY MESSAGES. HIV/AIDS Department BACKGROUND
KEY MESSAGES New WHO Recommendations: Antiretroviral therapy for adults and adolescents The World Health Organization (WHO) is revising its guidelines on antiretroviral therapy (ART) for adults and adolescents.
More informationStrategic use of antiretroviral drugs to prevent HIV transmission
Strategic use of antiretroviral drugs to prevent HIV transmission 22th Tunisian Congress of Infectious Diseases 2nd Congress of Federation of Arab Societies of Clinical Microbiology and Infectious Diseases
More informationTreat All : From Policy to Action - What will it take?
Strategy Finance Integration Cascade of services People centred Political Will Treat All : From Policy to Action - What will it take? Thursday, 9 June, 13.00 14.30 Conference Room 11, United Nations Questions
More informationWHO/NMH/TFI/11.3. Warning about the dangers of tobacco. Executive summary. fresh and alive
WHO/NMH/TFI/11.3 WHO REPORT on the global TOBACCO epidemic, 2011 Warning about the dangers of tobacco Executive summary fresh and alive World Health Organization 2011 All rights reserved. Publications
More informationCombination prevention: Public health and human rights imperatives
Combination prevention: Public health and human rights imperatives Gottfried Hirnschall, MD MPH HIV/AIDS Department WHO, Geneva London, June 11, 2012 Outline The epidemic and response What is combination
More informationDECLARATION ON ACCELERATION OF HIV PREVENTION EFFORTS IN THE AFRICAN REGION
DECLARATION ON ACCELERATION OF HIV PREVENTION EFFORTS IN THE AFRICAN REGION AFRO Library Cataloguing-in-Publication Data Declaration on Acceleration of HIV Prevention efforts in the African Region 1. Acquired
More informationMONITORING THE BUILDING BLOCKS OF HEALTH SYSTEMS: A HANDBOOK OF INDICATORS AND THEIR MEASUREMENT STRATEGIES
MONITORING THE BUILDING BLOCKS OF HEALTH SYSTEMS: A HANDBOOK OF INDICATORS AND THEIR MEASUREMENT STRATEGIES A WHO Library Cataloguing-in-Publication Data Monitoring the building blocks of health systems:
More informationTECHNICAL UPDATE HIV DRUG RESISTANCE HIV DRUG RESISTANCE SURVEILLANCE GUIDANCE: 2015 UPDATE
TECHNICAL UPDATE HIV DRUG RESISTANCE HIV DRUG RESISTANCE SURVEILLANCE GUIDANCE: 2015 UPDATE DECEMBER 2015 TECHNICAL UPDATE HIV DRUG RESISTANCE SURVEILLANCE GUIDANCE: 2015 UPDATE DECEMBER 2015 WHO Library
More informationINTERNAL QUESTIONS AND ANSWERS DRAFT
WHO CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION Background: INTERNAL QUESTIONS AND ANSWERS DRAFT At the end of 2012, 9.7 million people were receiving
More informationLatent tuberculosis infection
Latent tuberculosis infection Updated and consolidated guidelines for programmatic management ANNEX 3 Values and preferences for the management of latent tuberculosis infection: survey of populations affected
More informationSURVEILLANCE OF ANTIRETROVIRAL DRUG TOXICITY WITHIN ANTIRETROVIRAL TREATMENT PROGRAMMES. Main messages
TECHNICAL BRIEF SURVEILLANCE OF ANTIRETROVIRAL TOXICITY HIV/AIDS PROGRAMME SURVEILLANCE OF ANTIRETROVIRAL DRUG TOXICITY WITHIN ANTIRETROVIRAL TREATMENT PROGRAMMES OCTOBER 2013 This document provides guidance
More informationGuidelines for scaling-up the 100% condom use programme:
Guidelines for scaling-up the 100% condom use programme: Experience from Cambodia World Health Organization Regional Office for the Western Pacific Guidelines for scaling-up the 100% condom use programme:
More informationIntercountry meeting of national malaria programme managers from countries of HANMAT and PIAM-Net
WHO-EM/MAL/367/E Summary report on the Intercountry meeting of national malaria programme managers from countries of HANMAT and PIAM-Net Muscat, Oman 22 24 September 2011 World Health Organization 2012
More informationPreventing HIV Transmission in Intimate Partner Relationships
Preventing HIV Transmission in Intimate Partner Relationships Evidence, strategies and approaches for addressing concentrated HIV epidemics in Asia Executive Summary Proposed citation: UNDP (2015). Preventing
More informationNATIONAL AIDS PROGRAMME MANAGEMENT A SET OF TRAINING MODULES
NATIONAL AIDS PROGRAMME MANAGEMENT A SET OF TRAINING MODULES WHO Library Cataloguing-in-Publication data World Health Organization, Regional Office for South-East Asia. National AIDS programme management:
More informationWorld Health Organization. A Sustainable Health Sector
World Health Organization A Sustainable Health Sector Response to HIV Global Health Sector Strategy for HIV/AIDS 2011-2015 (DRAFT OUTLINE FOR CONSULTATION) Version 2.1 15 July 2010 15 July 2010 1 GLOBAL
More informationTechnical Guidance Note for Global Fund HIV Proposals
Technical Guidance Note for Global Fund HIV Proposals UNAIDS I World Health Organization I 2011 Rationale for including this activity in the proposal The World Health Organization (WHO), the Joint United
More informationChecklist for assessing the gender responsiveness of sexual and reproductive health policies. Pilot document for adaptation to national contexts
Checklist for assessing the gender responsiveness of sexual and reproductive health policies Pilot document for adaptation to national contexts Address requests about publications of the WHO Regional Office
More informationhiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants
hiv/aids Programme Programmatic update Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants EXECUTIVE SUMMARY April 2012 EXECUTIVE SUMMARY Recent developments
More informationGUIDANCE FOR SAMPLING ART CLINICS IN COUNTRIES COMBINING SURVEILLANCE OF PRE-TREATMENT HIV DRUG RESISTANCE AND ACQUIRED HIV DRUG RESISTANCE AT 12 AND
GUIDANCE FOR SAMPLING ART CLINICS IN COUNTRIES COMBINING SURVEILLANCE OF PRE-TREATMENT HIV DRUG RESISTANCE AND ACQUIRED HIV DRUG RESISTANCE AT 12 AND 48+ MONTHS DECEMBER 2017 Guidance For Sampling ART
More informationUNAIDS 99.1E (English original, March 1999) This document, presenting a speech given at the United Nations General Assembly Special Session on Drugs,
U N A I D S B E S T P R A C T I C E C O L L E C T I O N Drug use and HIV/AIDS UNAIDS statement presented at the United Nations General Assembly Special Session on Drugs Joint United Nations Programme on
More informationCUTANEOUS LEISHMANIASIS
CUTANEOUS LEISHMANIASIS Why are you neglecting me? A WHO initiative to control Cutaneous Leishmaniasis in selected Old World areas This document has been produced as the result of a WHO Informal Consultative
More informationLatent tuberculosis infection
Latent tuberculosis infection Updated and consolidated guidelines for programmatic management ANNEX 2 Evidence-to-Decision and GRADE tables Latent tuberculosis infection Updated and consolidated guidelines
More informationModule 9 Strategic information
National AIDS Programme Management A Training Course Module 9 Strategic information 2007 WHO Library Cataloguing-in-Publication data World Health Organization, Regional Office for South-East Asia. National
More informationTechnical Guidance Note for Round 11 Global Fund HIV Proposals
Technical Guidance Note for Round 11 Global Fund HIV Proposals UNAIDS I World Health Organization I 2011 Rationale for including HIVDR prevention and assessment in the proposal Situation analysis As access
More informationASEAN Declaration of Commitment on HIV and AIDS: Fast-Tracking and Sustaining HIV and AIDS Responses To End the AIDS Epidemic by 2030
ASEAN Declaration of Commitment on HIV and AIDS: Fast-Tracking and Sustaining HIV and AIDS Responses To End the AIDS Epidemic by 2030 1. WE, the Heads of State and Government of the Association of Southeast
More informationTechnical guidance for Round 9 Global Fund HIV proposals
Technical guidance for Round 9 Global Fund HIV proposals Broad Area Service Delivery Area TREATMENT Prevention and assessment of HIV drug resistance (HIVDR) This technical brief provides key information
More informationLEADING THE HEALTH SECTOR RESPONSE TO HIV/AIDS
WHO/HIV/2002.16 HIV/AIDS DEPARTMENT FAMILY AND COMMUNITY HEALTH CLUSTER LEADING THE HEALTH SECTOR RESPONSE TO HIV/AIDS HIV/AIDS Department Family and Community Health Cluster World Health Organization
More informationConcept note. 1. Background and rationale
Concept note Inter-Country Workshops for Strengthening Regional and National Human Capacity to Accelerate Scaling up of National PMTCT and Paediatric Care, Support and Treatment Programmes TOWARDS UNIVERSAL
More informationProgram to control HIV/AIDS
90-90-90 Program to control HIV/AIDS Hamid Sharifi Associate Professor in Epidemiology [sharifihami@gmail.com] 1 Targets for ending the AIDS epidemic 2 New HIV infections in low- and middle-income countries,
More information2004 Update. Luxembourg
2004 Update Luxembourg 2 Luxembourg HIV/AIDS estimates In 2003 and during the first quarter of 2004, UNAIDS and WHO worked closely with national governments and research institutions to recalculate current
More informationHIV & AIDS IN SOUTH AFRICA: WHERE ARE WE AND WHAT ARE
HIV & AIDS IN SOUTH AFRICA: WHERE ARE WE AND WHAT ARE THE REMAINING CHALLENGES DR YOGAN PILLAY, NDOH SA HIV CLINICIANS SOCIETY CONFERENCE, CAPE TOWN 25 NOVEMBER, 2012 GLOBAL DATA 34m people living with
More informationHIV Drug Resistance (HIVDR)
Technical Guidance Note for Round 10 Global Fund HIV Proposals HIV Drug Resistance (HIVDR) Rationale for including HIVDR prevention and assessment in the proposal June 2010 As access to ART services expands,
More informationThe President s Emergency Plan for AIDS Relief. Public Health Evaluations
The President s Emergency Plan for AIDS Relief Public Health Evaluations PEPFAR Evaluation Timeline Targeted Evaluations Public Health Evaluation Evaluation / Operations Research 2005 2006 2007 2008 2009
More informationPrevention of HIV in infants and young children
WHO/HIV/2002.08 Original: English Distr.: General Prevention of HIV in infants and young children A major public health problem HIV among children is a growing problem, particularly in the countries hardest
More informationGOOD PHARMACOPOEIAL PRACTICES
May 2013 RESTRICTED GOOD PHARMACOPOEIAL PRACTICES CONCEPT PAPER ON PURPOSE AND BENEFITS (MAY 2013) DRAFT FOR COMMENT Please address any comments on this proposal by 12 July 2013 to Dr S. Kopp, Medicines
More informationPhoto Book: Identify Signs of Illness
Integrated Management of Childhood Illness Caring for the Sick Child in the Community Photo Book: Identify Signs of Illness Photo 1 and 2. Chest indrawing Photo 3. Severe malnutrition (marasmus) Photo
More informationEnding AIDS in Gabon: How long will it take? How much will it cost?
Ending AIDS in Gabon: How long will it take? How much will it cost? Brian G. Williams, Eleanor Gouws* and David Ginsburg South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch,
More informationSecond intercountry meeting on the Eastern Mediterranean Acute Respiratory Infection Surveillance (EMARIS) network
Summary report on the Second intercountry meeting on the Eastern Mediterranean Acute Respiratory Infection Surveillance (EMARIS) network WHO-EM/CSR/070/E Sharm el-sheikh, Egypt 24 27 November 2013 Summary
More informationBUDGET AND RESOURCE ALLOCATION MATRIX
Strategic Direction/Function ILO Strengthened capacity of young people, youth-led organizations, key service providers and partners to develop, implement, monitor and evaluate HIV prevention programmes
More informationState of InequalIty. Reproductive, maternal, newborn and child health. executi ve S ummary
State of InequalIty Reproductive, maternal, newborn and child health executi ve S ummary WHO/HIS/HSI/2015.2 World Health Organization 2015 All rights reserved. Publications of the World Health Organization
More informationIARC Monographs on the Evaluation of Carcinogenic Risks to Humans. VOLUME 93 Carbon Black, Titanium Dioxide, and Talc
WORLD HEALTH ORGANIZATION INTERNATIONAL AGENCY FOR RESEARCH ON CANCER IARC Monographs on the Evaluation of Carcinogenic Risks to Humans VOLUME 93 Carbon Black, Titanium Dioxide, and Talc LYON, FRANCE 2010
More informationhiv/aids Programme programmatic update Antiretroviral Treatment as Prevention (TasP)
hiv/aids Programme programmatic update Antiretroviral Treatment as Prevention (TasP) of HIV and TB june 2012 Antiretroviral Treatment as Prevention (TasP) of HIV and TB: 2012 update WHO/HIV/2012.12 World
More informationKigali Province East Province North Province South Province West Province discordant couples
EXECUTIVE SUMMARY This report summarizes the processes, findings, and recommendations of the Rwanda Triangulation Project, 2008. Triangulation aims to synthesize data from multiple sources to strengthen
More informationThe Western Pacific Region faces significant
COMBATING COMMUNICABLE DISEASES A medical technician draws blood for HIV screening in Manila. AFP elimination of mother-to-child transmission of HIV and congenital syphilis was piloted in Malaysia and
More informationART for prevention the task ahead
ART for prevention the task ahead Dr Teguest Guerma WHO/HQS WHO's role and vision Status of the epidemic Overview Progress and challenges in treatment and prevention scale up ART for prevention Questions
More informationInvesting for Impact Prioritizing HIV Programs for GF Concept Notes. Lisa Nelson, WHO Iris Semini, UNAIDS
Investing for Impact Prioritizing HIV Programs for GF Concept Notes Lisa Nelson, WHO Iris Semini, UNAIDS Top 5 Lessons Learned 1 2 3 4 5 Prioritize within the allocation amount Separate above allocation
More informationTUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE CONTROL OF A DUAL EPIDEMIC IN THE WHO AFRICAN REGION. Report of the Regional Director.
30 August 2007 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Fifty-seventh session Brazzaville, Republic of Congo, 27 31 August Provisional agenda item 7.8 TUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE
More informationNATIONAL COORDINATION MECHANISM FOR TOBACCO CONTROL A Model for the African Region
NATIONAL COORDINATION MECHANISM FOR TOBACCO CONTROL A Model for the African Region I. World Health Organization. Regional Office for Africa II.Title ISBN 978-929023293-3 NLM Classification: WM 290) WHO
More informationUsing anti-hiv drugs for prevention
Using anti-hiv drugs for prevention Highlights from AIDS 2012 (and 2 nd International Workshops on Treatment as Prevention) Tim Rogers, trogers@catie.ca Using anti-hiv Drugs for Prevention Outline Treatment
More informationRegional workshop on updating national strategic plans for the prevention of re-establishment of local malaria transmission in malaria-free countries
Summary report on the Regional workshop on updating national strategic plans for the prevention of re-establishment of local malaria transmission in malaria-free countries Casablanca, Morocco 18 20 October
More informationFrom Africa to Georgia: What We Have Learned From the Treatment for All Initiative
From Africa to Georgia: What We Have Learned From the 90-90-90 Treatment for All Initiative Carlos del Rio, MD Professor of Global Health Rollins School of Public Health Professor of Medicine Emory University
More informationSummary report on the WHO-EM/WRH/104/E
Summary report on the Training of trainers course for national gynaecology and obstetrics societies and midwifery associations on evidence-based guidelines for strengthening family planning services WHO-EM/WRH/104/E
More informationThe road towards universal access
The road towards universal access Scaling up access to HIV prevention, treatment, care and support 22 FEB 2006 The United Nations working together on the road towards universal access. In a letter dated
More informationMONITORING HEALTH INEQUALITY
MONITORING HEALTH INEQUALITY An essential step for achieving health equity ILLUSTRATIONS OF FUNDAMENTAL CONCEPTS The examples in this publication draw from the topic of reproductive, maternal and child
More informationbiological agents volume 100 B A review of human carcinogens iarc monographs on the evaluation of carcinogenic risks to humans
biological agents volume 100 B A review of human carcinogens iarc monographs on the evaluation of carcinogenic risks to humans biological agents volume 100 B A review of human carcinogens This publication
More informationWHO Library Cataloguing-in-Publication Data. World health statistics 2011.
WORLD HEALTH STATISTICS 2011 WHO Library Cataloguing-in-Publication Data World health statistics 2011. 1.Health status indicators. 2.World health. 3.Health services - statistics. 4.Mortality. 5.Morbidity.
More informationScaling Up Treatment in Zimbabwe: The path to high coverage
Scaling Up Treatment in Zimbabwe: The path to high coverage IAS Conference Dr. Tsitsi Mutasa-Apollo ART Programme Coordinator, Zimbabwe 30 th June, 2013 Kuala Lumpur, Malaysia Outline Introduction Background
More information2004 Update. Georgia
24 Update Georgia 2 Georgia HIV/AIDS estimates In 23 and during the first quarter of 24, UNAIDS and WHO worked closely with national governments and research institutions to recalculate current estimates
More informationAdult rate (%) 0.1 Low estimate. 0.0 High estimate 0.2
2004 Update Fiji 2 Fiji HIV/AIDS estimates In 2003 and during the first quarter of 2004, UNAIDS and WHO worked closely with national governments and research institutions to recalculate current estimates
More informationEconomic and Social Council
United Nations Economic and Social Council Distr.: General 18 November 2014 Original: English Economic and Social Commission for Asia and the Pacific Asia-Pacific Intergovernmental Meeting on HIV and AIDS
More informationWHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC,
WHO/NMH/PND/7.4 WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 207 Monitoring tobacco use and prevention policies Executive summary fresh and alive World Health Organization 207 Some rights reserved. This
More informationFAST-TRACK COMMITMENTS TO END AIDS BY 2030
FAST-TRACK COMMITMENTS TO END AIDS BY 2030 FAST-TRACK COMMITMENTS TO END AIDS BY 2030 90-90-90 1 Ensure that 30 million people living with HIV have access to treatment through meeting the 90 90 90 targets
More informationNo adolescent living with HIV left behind: a coalition for action
May 2014 No adolescent living with HIV left behind: a coalition for action Participating organisations Asia Pacific Network of People Living with HIV African Young Positives CIPHER, International AIDS
More informationAPPROACH TO GEOGRPAPHIC AND/OR POPULATION FOCUS:
Sowing Sowing seeds MACO seeds of Hope of Hope May 2015 Civil society priority recommendations to the 2015 Zimbabwe SDS We support the priority placed by the PEPFAR COP 2015 global guidance on epidemic
More informationUNGASS COUNTRY PROGRESS REPORT Republic of Armenia
UNGASS COUNTRY PROGRESS REPORT Republic of Armenia Reporting period: January 2006 December 2007 I. Status at a glance The Armenia UNGASS Country Progress Report was developed under the overall guidance
More informationGender inequality and genderbased
UNAIDS 2016 REPORT Gender inequality and genderbased violence UBRAF 2016-2021 Strategy Result Area 5 2 Contents Achievements 2 Women and girls 2 Gender-based violence 6 Challenges 7 Key future actions
More informationADOLESCENTS AND HIV:
Elizabeth Glaser Pediatric AIDS Foundation Until no child has AIDS. Photo by Eric Bond/EGPAF, 2015 ADOLESCENTS AND HIV: PRIORITIZATION FOR ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION PROGRAMS, ADVOCACY
More informationWHO Global Health Sector Strategies HIV; Viral Hepatitis; Sexually Transmitted Infections
Common structure Universal Health Coverage SDGs Cascade of services Vision, Goals and Targets Costed Actions WHO Global Health Sector Strategies 2016-2021 HIV; Viral Hepatitis; Sexually Transmitted Infections
More informationTowards universal access
Key messages Towards universal access Scaling up priority HIV/AIDS interventions in the health sector September 2009 Progress report Towards universal access provides a comprehensive global update on progress
More informationHIV in Zambia MINISTRY OF HEALTH. Dr Albert Mwango, BScHB, MBChB, MPH National Antiretroviral Program Coordinator,
HIV in Zambia Dr Albert Mwango, BScHB, MBChB, MPH National Antiretroviral Program Coordinator, MINISTRY OF HEALTH 8th INTEREST WORKSHOP Intercontinental Hotel, Lusaka May 5 th -9 th, 2013 Background Clinical
More informationGetting to zero HIV new infections in Asia and the Pacific region: Possible or impossible dream?
Getting to zero HIV new infections in Asia and the Pacific region: Possible or impossible dream? Steven J. Kraus Director UNAIDS Regional Support Team, Asia and the Pacific Timothy D. Mastro Director,
More informationCopyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved ISBN
UNAIDS DATA TABLES 2011 Copyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved ISBN 978-92-9173-945-5 UNAIDS / JC2225E The designations employed and the presentation of
More informationPromoting FP/RH-HIV/AIDS Integration: A Summary of Global Health Initiative Strategies in Ethiopia, Kenya, Tanzania, and Zambia
Promoting FP/RH-HIV/AIDS Integration: A Summary of Global Health Initiative Strategies in Ethiopia, Kenya, Tanzania, and Zambia The Global Health Initiative (GHI) is an integrated approach to global health
More information90% 90% 90% 30% 10% 5% 70% 90% 95% WHY HIV SELF-TESTING? PLHIV diagnosed PLHIV undiagnosed
WHY HIV SELF-TESTING? In 2014, the United Nations set bold new targets, calling on the global community to ensure that by 2020, 90% of all people living with HIV will know their HIV status, 90% of all
More informationIFMSA Policy Statement Ending AIDS by 2030
IFMSA Policy Statement Ending AIDS by 2030 Proposed by IFMSA Team of Officials Puebla, Mexico, August 2016 Summary IFMSA currently acknowledges the HIV epidemic as a major threat, which needs to be tackled
More informationDiabetes. Halt the diabetes epidemic
Diabetes Halt the diabetes epidemic WHO Library Cataloguing in Publication Data World Health Organization. Regional Office for the Eastern Mediterranean Diabetes: halt the diabetes epidemic / World Health
More informationWhy are the targets a game-changer? What is the Fast-Track Cities Initiative and its connection to ?
Frequently Asked Questions about 90-90-90 Targets, the HIV Care Continuum, the Updated National HIV AIDS Strategy (NHAS), and the Fast-Track Cities Initiative What is the origin of the 90-90-90 targets?
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More information2004 Update. Serbia and Montenegro
2004 Update Serbia and Montenegro 2 Serbia and Montenegro HIV/AIDS estimates In 2003 and during the first quarter of 2004, UNAIDS and WHO worked closely with national governments and research institutions
More informationReview of the Democratic Republic of the Congo (DRC) by the Committee on the Elimination of Discrimination Against Women (CEDAW)
Review of the Democratic Republic of the Congo (DRC) by the Committee on the Elimination of Discrimination Against Women (CEDAW) Submission: Elizabeth Glaser Pediatric AIDS Foundation June 2013 Introduction:
More informationaids in asia and the pacific
HIV AIDS AND DEVELOPMENT IN ASIA AND THE PACIFIC a lengthening shadow aids in asia and the pacific World Health Organization Regional Offices for South East Asia and the Western Pacific Region 9 10 OCTOBER
More informationSex Work in Sub-Saharan Africa : Opportunities and Challenges
Sex Work in Sub-Saharan Africa : Opportunities and Challenges Dr Traore Isidore May 26, 2016 Definition of Sex Worker Female, male and transgender adults (18 years of age and above) who receive money or
More informationWhich Scale Up Strategies/Programmatic Mixes are most Cost-Effective? Iris Semini UNAIDS May 2018
Which Scale Up Strategies/Programmatic Mixes are most Cost-Effective? Iris Semini UNAIDS May 2018 Outline Scaling up for Impact Critical Point of the Response Choices of strategies Accelerating Implementation
More informationWHO/HIV_AIDS/BN/ Original: English Distr.: General
WHO/HIV_AIDS/BN/2001.1 Original: English Distr.: General It is estimated that 4.3 million children have died of AIDS before their fifteenth birthday, nearly half a million in 2000. Another 1.4 million
More informationASEAN Activities on Increasing Access to ARV and HIV Related Supplies
ASEAN Activities on Increasing Access to ARV and HIV Related Supplies Consultation on Integrating Prevention and Management of STI/HIV/AIDS into Reproductive, Maternal and Newborn Health Services and the
More informationTechnical Guidance Note for Global Fund HIV Proposals
Technical Guidance Note for Global Fund HIV Proposals UNAIDS I World Health Organization I August 2011 Rationale for including pharmacovigilance in the proposal Pharmacovigilance is the science and activities
More informationSouth Africa s National HIV Programme. Dr Zuki Pinini HIV and AIDS and STIs Cluster NDOH. 23 October 2018
South Africa s National HIV Programme Dr Zuki Pinini HIV and AIDS and STIs Cluster NDOH 23 October 2018 Overview The HIV and AIDS sub-programme at NDOH is responsible for: policy formulation, coordination,
More informationPrEP: Pre Exposure Prophylaxis
PrEP: Pre Exposure Prophylaxis Lyn Stevens, NP, MS, ACRN Deputy Director Office of the Medical Director NYS Department of Health, AIDS Institute Faculty Disclosure Lyn Stevens No relationships to disclose
More informationViiV Healthcare s Position on Prevention in HIV
ViiV Healthcare s Position on Prevention in HIV ViiV Healthcare is a company 100% committed to HIV, and we are always looking to move beyond the status quo and find new ways of navigating the challenges
More information2004 Update. Hungary
24 Update Hungary 2 Hungary HIV/AIDS estimates In 23 and during the first quarter of 24, UNAIDS and WHO worked closely with national governments and research institutions to recalculate current estimates
More informationHIV/AIDS estimates. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance. UNAIDS/WHO Epidemiological Fact Sheet Update.
24 Update Bhutan 2 Bhutan HIV/AIDS estimates In 23 and during the first quarter of 24, UNAIDS and WHO worked closely with national governments and research institutions to recalculate current estimates
More informationGuideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV
Web supplement to Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV ISBN 978 92 4 150956 5 Guideline on when to start antiretroviral therapy and on pre-exposure
More information2004 Update. Seychelles
2004 Update Seychelles 2 Seychelles HIV/AIDS estimates In 2003 and during the first quarter of 2004, UNAIDS and WHO worked closely with national governments and research institutions to recalculate current
More informationTRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES
POLICY BRIEF HIV TREATMENT TRANSITION TO NEW ANTIRETROVIRALS IN HIV PROGRAMMES JULY 2017 WHO This policy brief provides advice on a phased approach to transitioning to new WHO-recommended HIV treatment
More information7.5 South-East Asian Region: summary of planned activities, impact and costs
PART II: GLOBAL AND REGIONAL SCENARIOS FOR TB CONTROL 26 215 7.5 South-East Asian Region: summary of planned activities, impact and costs Achievements DOTS expanded rapidly in the South-East Asian Region
More informationContextual overview with reference to MDG Goal 6 and projection for Post-2015
Contextual overview with reference to MDG Goal 6 and projection for Post-2015 10th Partnership Annual Conference Side Event Combating HIV and TB through a joint regional action Helsinki, Finland November
More information